GSK and Dong-A - Top 5 Emerging Market Deals

Who: GlaxoSmithKline
With: Dong-A Pharmaceuticals
Where: South Korea

Deal Size: $114 million

Details: In May GSK bought itself a 9.9 percent stake in Dong-A Pharmaceuticals, the number one pharma and OTC drugmaker in the fast-growing South Korean market. As part of the agreement, Dong-A will co-promote a roster of GSK primary-care products.

The Korean pharmaceutical market has been experience impressive pharma market growth (13.9% CAGR 2006-08), and was the 13th largest pharmaceutical market in the world in 2008. The market is expected to continue its double-digit growth spurt through to 2012. Prior to the deal, GSK was ranked fifth amount South Korean drugmakers with 2009 sales of $333.6 million. 

Related Articles:
GSK beefs up in S. Korea with Dong-A alliance
Global drug sales will hit $1 trillion by 2014
GSK stakes its emerging markets claim
GSK aims at prices in middle-income countries